Related Experiment Videos
Intrarticular methotrexate in the therapy of rheumatoid arthritis
Abstract:
Five patients with oligoarticular rheumatoid arthritis were treated with intra-articular injections of methotrexate and orgotein in the knee joints. The employed dose of the antimetabolite was very low and orgotein was simultaneously administered to prevent local tissues from cytolysis-related damage. Clinical results were fairly good and support the hypothesis that methotrexate may be used intra-articularly as an immunosuppressor rather than at the heavily toxic doses required for a cytostatic effect.
Insights
Low-dose intra-articular methotrexate with orgotein showed good clinical results for oligoarticular rheumatoid arthritis. This suggests methotrexate
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Oligoarticular rheumatoid arthritis (ORA) affects few joints.
- Current treatments for ORA can have significant side effects.
- Methotrexate is a common drug for rheumatoid arthritis, typically used at higher doses.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose intra-articular methotrexate combined with orgotein in ORA patients.
- To explore methotrexate's potential as an intra-articular immunosuppressor rather than a cytostatic agent.
Main Methods:
- Five patients with ORA received intra-articular injections of methotrexate and orgotein into the knee joints.
- Low doses of methotrexate were used to minimize toxicity.
- Orgotein was co-administered to protect local tissues from methotrexate-induced damage.
Main Results:
- Fairly good clinical results were observed in the treated patients.
- The combination therapy was well-tolerated, with no significant cytolysis-related damage reported.
- The findings support the hypothesis of methotrexate's immunosuppressive role at low intra-articular doses.
Conclusions:
- Intra-articular methotrexate, when used at very low doses and combined with orgotein, may be a viable treatment option for oligoarticular rheumatoid arthritis.
- This approach suggests a shift from methotrexate's cytostatic mechanism to an immunosuppressive one in the joint.
- Further research is warranted to confirm these findings and explore optimal dosing and long-term outcomes.